Lipid panel on GLP-1 therapy: total, LDL, HDL and triglycerides, the healthy levels, and when to repeat

A lipid panel is four numbers from one tube: total cholesterol, LDL, HDL and triglycerides. Some reports add non-HDL cholesterol (total minus HDL) and a note that the LDL was "calculated" rather than measured. None of the four is a GLP-1 monitoring requirement. All four are on almost every baseline panel, because weight and cardiovascular risk are the reason most people are in the room.

What each number is

Total cholesterol is everything added together. LDL is the fraction that deposits in artery walls; it is the number most treatment decisions are made on. HDL is the fraction associated with lower risk; higher is better, within reason. Triglycerides are a different kind of fat, sensitive to recent meals, alcohol, sugar intake and insulin resistance. MedlinePlus notes the LDL on your report may say "calculated", meaning it was estimated from the other three; when triglycerides are very high the estimate is unreliable and a direct LDL is measured instead.

The healthy levels

For adults 20 and older, MedlinePlus lists: total cholesterol under 200 mg/dL, non-HDL under 130 mg/dL, LDL under 100 mg/dL, and HDL of 60 mg/dL or higher as best, with under 40 mg/dL (men) or under 50 mg/dL (women) considered low. For triglycerides: under 150 mg/dL normal, 150 to 199 borderline high, 200 to 499 high, 500 or above very high.

These are population screening levels. The LDL a clinician wants for you depends on your risk. People with established cardiovascular disease or diabetes are commonly set targets well below 100 mg/dL. That decision uses a risk calculation, not this page.

Why it is drawn before GLP-1 therapy

It is part of the reason for treatment. Wegovy carries an indication to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. The lipid panel is one of the inputs to whether someone has that risk profile.

It is the ADA baseline. For people with diabetes, the Standards of Care include a lipid profile at diagnosis and at the initial medical evaluation. Starting a GLP-1 is often the first time in years that a full panel is drawn.

It gives you a before. Weight loss usually moves triglycerides more than it moves LDL. Without a baseline you cannot see either.

How often it is repeated

No GLP-1 label sets a lipid interval. The ADA Standards give the closest thing to a schedule: in adults not on lipid-lowering therapy, a lipid profile at diagnosis, at the initial evaluation, and then every 5 years if under 40 (more often if indicated); for people on a statin, a panel 4 to 12 weeks after starting or changing the dose, then annually. Many prescribers repeat the panel at the 6 or 12 month GLP-1 review because the weight has changed enough to make the comparison interesting. That is a choice, not a requirement.

What SELECT showed, and what it did not

SELECT randomised 17,604 adults aged 45 or older with pre-existing cardiovascular disease and a BMI of 27 or higher, without diabetes, to semaglutide 2.4 mg weekly or placebo. Over a mean follow-up of about 40 months the primary cardiovascular outcome occurred in 6.5% of the semaglutide group and 8.0% of the placebo group (hazard ratio 0.80; 95% CI 0.72 to 0.90). That is the trial behind the Wegovy cardiovascular indication.

It did not show that semaglutide replaces a statin, and it did not enrol people without established cardiovascular disease. Lipid changes in the trial were secondary; the headline result was events. If your lipid panel is the thing you want to change, the tools for that are diet, statins and other lipid therapies, decided with your clinician.

What to discuss with your prescriber

• Whether your panel should be fasting, and keeping that consistent for later comparison.
• What LDL your clinician wants for you and why (your risk category, not the population range).
• Whether a very high triglyceride result changes anything about starting therapy.
• If you take a statin: when the next panel and liver enzymes are due, since those are usually drawn together.

The FormBlends GLP-1 overview explains where a compounded program sits relative to the brand products; compounded semaglutide and tirzepatide are not FDA approved and are not covered by the SELECT indication or any other label indication.